Changes in serum estrogen levels in women during tamoxifen therapy

American Journal of Surgery
S S LumR F Pommier

Abstract

Tamoxifen is considered an antiestrogen against breast cancer, yet it has known estrogenic side effects. We hypothesized that long-term administration of tamoxifen may significantly increase circulating estrogen levels in women with breast cancer. Serum dehydroepiandrosterone (DHEA), estrone (E1), and estradiol (E2) levels were prospectively measured in 47 breast cancer patients before and during tamoxifen therapy for 2 years. Differences in baseline and peak hormone levels during treatment were compared, and significance was determined by paired Student's t test. Mean DHEA levels increased by 133% from 61 mg/L to 142 mg/L (P <0.001) and mean E2 levels increased by 239% from 28 pg/mL to 95 pg/mL (P <0.05). Mean E1 levels increased by 264% from 42 pg/mL to 153 pg/mL (P = 0.06). Long-term tamoxifen therapy can be associated with increased serum levels of DHEA, E1, and E2. Elevated serum estrogens may explain tamoxifen's estrogenic effects and may represent a mechanism for the development of drug resistance.

References

Aug 1, 1979·The Journal of Clinical Investigation·B M ShermanD Wycoff
Feb 1, 1979·Cancer·A ManniO H Pearson

❮ Previous
Next ❯

Citations

Jan 16, 2002·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Y Iino
Jul 10, 2010·The Breast : Official Journal of the European Society of Mastology·Eitan AmirMark Clemons
Mar 8, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Cheryl L RockUNKNOWN Women's Healthy Eating and Living Study Group
Dec 3, 2013·Endocrine-related Cancer·Claudia BozzaLucia Del Mastro
Feb 14, 2012·Climacteric : the Journal of the International Menopause Society·T Kunovac KallakK Nilsson
Apr 30, 2002·Oncology Nursing Forum·Janet S CarpenterMichael Andrykowski
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cheryl L RockR Jeffrey Chang
Jul 10, 2004·Menopause : the Journal of the North American Menopause Society·Janet S CarpenterRobert R Freedman
May 17, 2001·Menopause : the Journal of the North American Menopause Society·J S CarpenterM Andrykowski
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Anthony J LeeBao Ting Zhu
Dec 18, 2001·The Oncologist·L B MichaudA U Buzdar
Sep 10, 2020·Journal of Cellular Physiology·Mitrasadat RezaeiRamin Pouriran
Aug 10, 1999·Journal of Surgical Oncology·L A NewmanS E Singletary
Jul 15, 2020·Seminars in Oncology·Jonathan D StropeWilliam D Figg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sarah RodriguezLinda Emanuel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Clarisa R Gracia, Jacqueline S Jeruss
© 2021 Meta ULC. All rights reserved